Based on the existing varieties, brands, channels and marketing advantages, Jointown conducts targeted development of self-operated industrial and OEM products by virtue of big data accumulated by the Company's "hundred-billion-level" supply chain service platform, and then distributes pharmaceuticals to terminal or C-end consumers through its full-channel sales network.

In terms of pharmaceutical production, the Company's subsidiary Beijing Jingfeng Pharmaceutical Group Co., Ltd. (hereinafter referred to as "Jingfeng Pharmaceutical") currently holds over 300 approved drug registration numbers, with products covering more than 10 dosage forms and over 170 products in production. The main product series include antidiabetic drugs, topical medications, anti-infective and respiratory drugs, cardiovascular drugs, and nervous system drugs, featuring star products such as the "Metformin" series and Compound Clotrimazole Cream. In terms of drug research and development, Jingfeng Pharmaceutical focuses on four major therapeutic areas: antidiabetic, topical, cardiovascular and cerebrovascular, and anti-infective drugs. Currently, 12 drug varieties have passed consistency evaluation, with new products under development including 11 active pharmaceutical ingredients (APIs) and 25 formulations. In the future, Jingfeng Pharmaceutical will establish a dual-track model for its chronic disease management (Type II Diabetes and Topical Medications), offering a holistic health service system for chronic disease patients.

Jiuxin TCM Group Co., Ltd. (hereinafter referred to as "Jiuxin TCM") focuses on the development of Daodi Herbs and Chinese herbal pieces, strategically positioning itself across the entire TCM industry chain. It is committed to producing high-quality, safe, and reliable TCM products. The company develops six series of products—ordinary herbal pieces, refined herbal pieces, directly consumable herbal pieces, toxic herbal pieces, ginseng and deer antler delicacies, and health foods—under the brands "Jiuxin", "JoinNative", "Jingui Dejitang", "Jiuxintang", and "Zhenyang" to cater to diverse market demands. Meanwhile, Jiuxin TCM has expanded into four major marketing segments: OTC business, medical business, herbal medicine business, and online business. Furthermore, Jiuxin TCM has initiated brand strategy restructuring and strategic expansion of product categories: on the brand front, with "Daodi Herbs, Made by Jiuxin" as the core, optimizing the "1+N" architecture design and strengthening the synergistic effects between primary and secondary brands; on the product front, focusing on channel characteristics to develop core flagship products, expanding comprehensive health consumer products such as medicine-food homologous items and agricultural by-products, enriching product categories and pipelines, thereby further strengthening brand core competitiveness and product market penetration, and consolidating its leading position in China's traditional Chinese medicinal materials and herbal pieces industry.

Wuhan KENIZI Medical Technology Co., Ltd. (hereinafter referred to as "KENIZI"), a subsidiary of Jointown, operates in areas such as R&D registration, clinical services, product marketing, and production management. It has registered two proprietary brands, Metiko and Flo's, obtained 16 Class II product registration certificates and 28 Class I product filing certificates, and has OEM device product specifications totaling 280. In Q1-Q3, 2025, KENIZI launched 7 new products approved for market sale, including proprietary patented drainage bags, 2 MAH self-held certificate products, and 3 OEM products. Through independent R&D and the production of its own brand and OEM products, Jointown has developed products with independent intellectual property rights and exclusive sales rights, thereby enhancing product competitiveness. At the same time, the Company continuously explores external sales channels to expand market coverage, steadily increasing market share and promoting sustained development in the medical device industry and OEM business sectors.